Polymyalgia rheumatica and giant-cell arteritis

C Salvarani, F Cantini, L Boiardi… - New England Journal of …, 2002 - Mass Medical Soc
Polymyalgia rheumatica is an inflammatory disorder manifested principally by stiffness of the
neck, shoulder girdle, and pelvic girdle; giant-cell (or temporal) arteritis affects the cranial …

Polymyalgia rheumatica and giant-cell arteritis

C Salvarani, F Cantini, GG Hunder - The Lancet, 2008 - thelancet.com
Polymyalgia rheumatica and giant-cell arteritis are closely related disorders that affect people
of middle age and older. They frequently occur together. Both are syndromes of unknown …

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

…, G Tocci, R Scarpa, D Goletti, F Cantini - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative …

…, A Iagnocco, C Nannini, F Cantini… - Arthritis & …, 2012 - Wiley Online Library
The objective of this study was to develop European League Against Rheumatism/American
College of Rheumatology classification criteria for polymyalgia rheumatica (PMR). …

[HTML][HTML] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

F Cantini, L Niccoli, D Matarrese, E Nicastri… - The Journal of …, 2020 - ncbi.nlm.nih.gov
As discussed in the Journal recently1 the SARS-CoV-2, a new β-Coronavirus, uses the
Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is mediated …

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

…, YJ Tan, V Monteil, G Dranitsaris, F Cantini… - Science …, 2021 - science.org
Using AI, we identified baricitinib as having antiviral and anticytokine efficacy. We now show
a 71% (95% CI 0.15 to 0.58) mortality benefit in 83 patients with moderate-severe SARS-…

Risk factors for visual loss in an Italian population‐based cohort of patients with giant cell arteritis

…, P Macchioni, D Consonni, F Cantini… - Arthritis Care & …, 2005 - Wiley Online Library
Objective To evaluate the frequency of visual manifestations at presentation in an Italian
population‐based cohort of patients with biopsy‐proven giant cell arteritis (GCA), and to …

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

F Cantini, L Niccoli, C Nannini, D Matarrese… - Journal of …, 2020 - journalofinfection.com
We note with interest the study of Liu et al. 1 where they used routine laboratory test parameters
to derive a potentially useful, independent measure (neutrophil–lymphocyte ratio–NLR) …

[HTML][HTML] A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

…, A Antinori, A Vergori, N Caccamo, F Cantini… - Clinical microbiology …, 2021 - Elsevier
Objectives To examine whether specific T-cell-responses to SARS-CoV-2 peptides can be
detected in COVID-19 using a whole-blood experimental setting, which may be further …

Coenzyme Q10 in essential hypertension

V Digiesi, F Cantini, A Oradei, G Bisi… - Molecular aspects of …, 1994 - Elsevier
This study was undertaken to clarify the mechanism of the antihypertensive effect of coenzyme
Q 10 (CoQ 10 ). Twenty-six patients with essential arterial hypertension were treated with …